{"success":true,"data":{"pressRelease":{"id":"131391","rtpr_id":"nACSFDKr6a","ticker":"TNON","exchange":"NASDAQ","all_tickers":["TNON"],"title":"Tenon Medical Announces Closing of $3M Private Placement Offering ","author":"ACCESSWIRE","published_at":"2026-08-31T15:45:55.734Z","article_body":"LOS GATOS, CA / ACCESS Newswire (https://www.accessnewswire.com/) / August 31,\n2026 / Tenon Medical, Inc. (https://pr.report/pqbv) (Nasdaq:TNON), a medical\ndevice company dedicated to transforming care for patients with certain\nsacro-pelvic disorders, has closed its previously announced private placement\npursuant to securities purchase agreement with an institutional investor to\nsell 597,610 shares of common stock (or pre-funded warrants in lieu thereof),\ntogether with a warrant to purchase up to an aggregate 1,058,517 shares of\ncommon stock, in a private placement offering. The combined effective offering\nprice for each share of common stock and accompanying warrants to be issued is\n$5.02. The combined effective offering price for each pre-funded warrant and\naccompanying warrants to be issued is $5.019. The pre-funded warrants will\nhave an exercise price of $0.001 per share of common stock and the warrant\nwill have an exercise price of $5.02 per share, will be immediately\nexercisable, and will expire five years from the date of issuance.\n\nThe gross proceeds to the Company from the offering are estimated to be\napproximately $3.0 million before deducting the placement agent's fees and\nother estimated offering expenses.\n\nWallachBeth Capital LLC acted as the exclusive placement agent in connection\nwith the offering.\n\nThe offer and sale of the foregoing securities are being made in a private\nplacement under Section 4(a)(2) of the Securities Act of 1933, as amended (the\n\"Securities Act\"), and/or Regulation D promulgated thereunder, and the\nsecurities have not been registered under the Securities Act or applicable\nstate securities laws. Accordingly, the securities may not be reoffered or\nresold in the United States except pursuant to an effective registration\nstatement or an applicable exemption from the registration requirements of the\nSecurities Act and such applicable state securities laws. Pursuant to the\nterms of the securities purchase agreement, the Company has agreed to provide\ncustomary registration rights for the shares of common stock and the shares of\ncommon stock underlying the warrants and pre-funded warrants.\n\nThis press release does not constitute an offer to sell or the solicitation of\nan offer to buy the securities, nor shall there be any sale of the securities\nin any state in which such offer, solicitation or sale would be unlawful prior\nto the registration or qualification under the securities laws of such state.\nAny offering of the securities under the resale registration statement will\nonly be made by means of a prospectus.\n\nAbout Tenon Medical, Inc.\n\nTenon Medical, Inc. is a medical device company dedicated to transforming care\nfor patients with certain sacro-pelvic disorders. Tenon was incorporated in\nthe State of Delaware in 2012 and currently offers two systems to treat a\ndiseased sacroiliac joint (the \"SI Joint\"). The Company has developed The\nCatamaran™ SI Joint Fusion System that offers a novel, less invasive\napproach to the SI Joint using a single, robust titanium implant. In August\n2025, the Company acquired substantially all of the assets of SiVantage, Inc.\nand SIMPL Medical, LLC, including the SImmetry+® SI Joint Fusion System,\nwhich treats disorders of the SI Joint through a minimally invasive lateral\naccess solution that incorporates well-established orthopedic fusion\nprinciples. Since the national launch of The Catamaran System in October 2022,\nTenon is focused on three commercial opportunities: 1) primary SI Joint\nprocedures, 2) revision procedures of failed SI Joint implants and 3) SI-Joint\nfusion adjunct to a spine fusion construct.\n\nFor more information, please visit www.tenonmed.com. Information on the\nCompany's website does not constitute a part of and is not incorporated by\nreference into this press release.\n\nThe Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®,\nETAD®, Posterior Inferior Sacroiliac Fusion®, CAT SIJ Fusion System®,\nCatamaran SIJ Fusion System®, Catamaran Inferior Posterior Fusion System®,\nCatamaran Transfixation Fusion System®, Catamaran Transfixation Fusion\nDevice®, SImmetry® are registered trademarks of Tenon Medical, Inc.\nMAINSAIL™, and SImmetry+ are also trademarks of Tenon Medical, Inc.\n\nForward-Looking Statements\n\nThis press release contains \"forward-looking statements,\" which are statements\nrelated to events, results, activities or developments that Tenon expects,\nbelieves or anticipates will or may occur in the future. Forward-looking\nstatements often contain words such as \"intends,\" \"estimates,\" \"anticipates,\"\n\"hopes,\" \"projects,\" \"plans,\" \"expects,\" \"seek,\" \"believes,\" \"see,\" \"should,\"\n\"will,\" \"would,\" \"target,\" and similar expressions and the negative versions\nthereof. These forward-looking statements, include, but are not limited to,\nstatements regarding the completion of the offering, the satisfaction of\ncustomary closing conditions related to the offering and the anticipated use\nof proceeds therefrom. Such statements are based on Tenon's experience and\nperception of current conditions, trends, expected future developments and\nother factors it believes are appropriate under the circumstances, and speak\nonly as of the date made. Forward-looking statements are inherently uncertain\nand actual results may differ materially from assumptions, estimates or\nexpectations reflected or contained in the forward-looking statements as a\nresult of various factors. For details on the uncertainties that may cause\nTenon's actual results to be materially different than those expressed in any\nforward-looking statements, please review Tenon's Annual Report on Form 10-K\nfor the fiscal year ended December 31, 2025 and updated from time to time in\nour Form 10-Q filings and in our other public filings on file with the SEC at\nwww.sec.gov, particularly the information contained in the section entitled\n\"Risk Factors.\" We undertake no obligation to publicly update or revise any\nforward-looking statements to reflect new information or future events or\notherwise unless required by law.\n\nInvestor Contact\n\nShannon Devine\nMZ North America\n203-741-8811\ntenon@mzgroup.us\n\nSOURCE: Tenon Medical\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/education/tenon-medical-announces-closing-of-3m-private-placement-offering-1214709)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSFDKr6a","title":"Tenon Medical Announces Closing of $3M Private Placement Offering ","author":"ACCESSWIRE","ticker":"TNON","created":"2026-08-31T15:45:55.734Z","tickers":["TNON"],"exchange":"NASDAQ","article_body":"LOS GATOS, CA / ACCESS Newswire (https://www.accessnewswire.com/) / August 31,\n2026 / Tenon Medical, Inc. (https://pr.report/pqbv) (Nasdaq:TNON), a medical\ndevice company dedicated to transforming care for patients with certain\nsacro-pelvic disorders, has closed its previously announced private placement\npursuant to securities purchase agreement with an institutional investor to\nsell 597,610 shares of common stock (or pre-funded warrants in lieu thereof),\ntogether with a warrant to purchase up to an aggregate 1,058,517 shares of\ncommon stock, in a private placement offering. The combined effective offering\nprice for each share of common stock and accompanying warrants to be issued is\n$5.02. The combined effective offering price for each pre-funded warrant and\naccompanying warrants to be issued is $5.019. The pre-funded warrants will\nhave an exercise price of $0.001 per share of common stock and the warrant\nwill have an exercise price of $5.02 per share, will be immediately\nexercisable, and will expire five years from the date of issuance.\n\nThe gross proceeds to the Company from the offering are estimated to be\napproximately $3.0 million before deducting the placement agent's fees and\nother estimated offering expenses.\n\nWallachBeth Capital LLC acted as the exclusive placement agent in connection\nwith the offering.\n\nThe offer and sale of the foregoing securities are being made in a private\nplacement under Section 4(a)(2) of the Securities Act of 1933, as amended (the\n\"Securities Act\"), and/or Regulation D promulgated thereunder, and the\nsecurities have not been registered under the Securities Act or applicable\nstate securities laws. Accordingly, the securities may not be reoffered or\nresold in the United States except pursuant to an effective registration\nstatement or an applicable exemption from the registration requirements of the\nSecurities Act and such applicable state securities laws. Pursuant to the\nterms of the securities purchase agreement, the Company has agreed to provide\ncustomary registration rights for the shares of common stock and the shares of\ncommon stock underlying the warrants and pre-funded warrants.\n\nThis press release does not constitute an offer to sell or the solicitation of\nan offer to buy the securities, nor shall there be any sale of the securities\nin any state in which such offer, solicitation or sale would be unlawful prior\nto the registration or qualification under the securities laws of such state.\nAny offering of the securities under the resale registration statement will\nonly be made by means of a prospectus.\n\nAbout Tenon Medical, Inc.\n\nTenon Medical, Inc. is a medical device company dedicated to transforming care\nfor patients with certain sacro-pelvic disorders. Tenon was incorporated in\nthe State of Delaware in 2012 and currently offers two systems to treat a\ndiseased sacroiliac joint (the \"SI Joint\"). The Company has developed The\nCatamaran™ SI Joint Fusion System that offers a novel, less invasive\napproach to the SI Joint using a single, robust titanium implant. In August\n2025, the Company acquired substantially all of the assets of SiVantage, Inc.\nand SIMPL Medical, LLC, including the SImmetry+® SI Joint Fusion System,\nwhich treats disorders of the SI Joint through a minimally invasive lateral\naccess solution that incorporates well-established orthopedic fusion\nprinciples. Since the national launch of The Catamaran System in October 2022,\nTenon is focused on three commercial opportunities: 1) primary SI Joint\nprocedures, 2) revision procedures of failed SI Joint implants and 3) SI-Joint\nfusion adjunct to a spine fusion construct.\n\nFor more information, please visit www.tenonmed.com. Information on the\nCompany's website does not constitute a part of and is not incorporated by\nreference into this press release.\n\nThe Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®,\nETAD®, Posterior Inferior Sacroiliac Fusion®, CAT SIJ Fusion System®,\nCatamaran SIJ Fusion System®, Catamaran Inferior Posterior Fusion System®,\nCatamaran Transfixation Fusion System®, Catamaran Transfixation Fusion\nDevice®, SImmetry® are registered trademarks of Tenon Medical, Inc.\nMAINSAIL™, and SImmetry+ are also trademarks of Tenon Medical, Inc.\n\nForward-Looking Statements\n\nThis press release contains \"forward-looking statements,\" which are statements\nrelated to events, results, activities or developments that Tenon expects,\nbelieves or anticipates will or may occur in the future. Forward-looking\nstatements often contain words such as \"intends,\" \"estimates,\" \"anticipates,\"\n\"hopes,\" \"projects,\" \"plans,\" \"expects,\" \"seek,\" \"believes,\" \"see,\" \"should,\"\n\"will,\" \"would,\" \"target,\" and similar expressions and the negative versions\nthereof. These forward-looking statements, include, but are not limited to,\nstatements regarding the completion of the offering, the satisfaction of\ncustomary closing conditions related to the offering and the anticipated use\nof proceeds therefrom. Such statements are based on Tenon's experience and\nperception of current conditions, trends, expected future developments and\nother factors it believes are appropriate under the circumstances, and speak\nonly as of the date made. Forward-looking statements are inherently uncertain\nand actual results may differ materially from assumptions, estimates or\nexpectations reflected or contained in the forward-looking statements as a\nresult of various factors. For details on the uncertainties that may cause\nTenon's actual results to be materially different than those expressed in any\nforward-looking statements, please review Tenon's Annual Report on Form 10-K\nfor the fiscal year ended December 31, 2025 and updated from time to time in\nour Form 10-Q filings and in our other public filings on file with the SEC at\nwww.sec.gov, particularly the information contained in the section entitled\n\"Risk Factors.\" We undertake no obligation to publicly update or revise any\nforward-looking statements to reflect new information or future events or\notherwise unless required by law.\n\nInvestor Contact\n\nShannon Devine\nMZ North America\n203-741-8811\ntenon@mzgroup.us\n\nSOURCE: Tenon Medical\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/education/tenon-medical-announces-closing-of-3m-private-placement-offering-1214709)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-08-31T15:45:55.783121473Z","server_sent_at_ms":1788191155783},"received_at":"2026-08-31T15:45:55.842Z","source_url":"https://www.accessnewswire.com/newsroom/en/education/tenon-medical-announces-closing-of-3m-private-placement-offering-1214709"},"analysis":{"id":"120298","press_release_id":"131391","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"offering","narrative":"Tenon Medical closed a $3.0 million private placement, selling 597,610 shares of common stock along with warrants to purchase up to 1,058,517 shares.\n\nThe combined effective offering price was $5.02 per share and accompanying warrant; warrants are exercisable immediately and expire in five years.\n\nWallachBeth Capital acted as the exclusive placement agent for the offering, which was conducted under Regulation D.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine small-cap capital raise; low signal."},"keyFigures":{"dealValueUsd":3000000,"offeringPrice":5.02,"sharesOffered":597610,"customDimensions":{"warrants_included":1058517,"warrant_expiration":"five years","warrant_exercise_price":"$5.02","pre_funded_warrants_exercise_price":"$0.001"}},"quotedText":"The gross proceeds to the Company from the offering are estimated to be approximately $3.0 million before deducting the placement agent's fees and other estimated offering expenses.","namedEntities":{"people":[{"name":"Shannon Devine","role":"Investor Contact"}],"products":["The Catamaran™ SI Joint Fusion System","SImmetry+® SI Joint Fusion System"],"companies":[{"name":"Tenon Medical, Inc.","ticker":"TNON"},{"name":"WallachBeth Capital LLC","relationship":"placement agent"},{"name":"MZ North America","relationship":"IR firm"},{"name":"SiVantage, Inc.","relationship":"acquired asset"},{"name":"SIMPL Medical, LLC","relationship":"acquired asset"}],"dollarAmounts":[{"amount":"$3.0 million","context":"gross proceeds from the offering"},{"amount":"$5.02","context":"combined effective offering price per share and warrants"},{"amount":"$5.019","context":"combined effective offering price per pre-funded warrant and warrants"}]},"materialImpact":{"score":2,"reasoning":"A $3M private placement is a routine capital raise for a small-cap medical device company. While dilutive, the proceeds are not material enough on their own to be a major market-moving event for a company of this scale, nor is the discount or warrant coverage explicitly flagged as severe."},"tickerRelevance":{"others":[],"primary":"TNON"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"small_private_placement","sectorWeight":"niche_medical_device"}},"event_type":"offering","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"Tenon Medical closed a $3.0 million private placement, selling 597,610 shares of common stock along with warrants to purchase up to 1,058,517 shares.\n\nThe combined effective offering price was $5.02 per share and accompanying warrant; warrants are exercisable immediately and expire in five years.\n\nWallachBeth Capital acted as the exclusive placement agent for the offering, which was conducted under Regulation D.","key_figures":{"dealValueUsd":3000000,"offeringPrice":5.02,"sharesOffered":597610,"customDimensions":{"warrants_included":1058517,"warrant_expiration":"five years","warrant_exercise_price":"$5.02","pre_funded_warrants_exercise_price":"$0.001"}},"named_entities":{"people":[{"name":"Shannon Devine","role":"Investor Contact"}],"products":["The Catamaran™ SI Joint Fusion System","SImmetry+® SI Joint Fusion System"],"companies":[{"name":"Tenon Medical, Inc.","ticker":"TNON"},{"name":"WallachBeth Capital LLC","relationship":"placement agent"},{"name":"MZ North America","relationship":"IR firm"},{"name":"SiVantage, Inc.","relationship":"acquired asset"},{"name":"SIMPL Medical, LLC","relationship":"acquired asset"}],"dollarAmounts":[{"amount":"$3.0 million","context":"gross proceeds from the offering"},{"amount":"$5.02","context":"combined effective offering price per share and warrants"},{"amount":"$5.019","context":"combined effective offering price per pre-funded warrant and warrants"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-31T15:50:51.373Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"small_private_placement","sectorWeight":"niche_medical_device"}},"durationMs":190452,"modelName":"glm-4.7"}}